Medpace Holdings, Inc. (MEDP)

Market Cap	12.53B
Revenue (ttm)	1.96B
Net Income (ttm)	312.51M
Shares Out	30.98M
EPS (ttm)	9.81
PE Ratio	41.23
Forward PE	35.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	197,372
Open	406.20
Previous Close	407.24
Day's Range	400.10 - 411.55
52-Week Range	227.21 - 437.39
Beta	1.39
Analysts	Strong Buy
Price Target	447.14 (+10.56%)
Earnings Date	Jul 22, 2024

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 5,900
• Stock Exchange: NASDAQ
• Ticker Symbol: MEDP

Financial Performance

In 2023, MEDP's revenue was $1.89 billion, an increase of 29.17% compared to the previous year's $1.46 billion. Earnings were $282.81 million, an increase of 15.26%.

Analyst Forecast

According to 7 analysts, the average rating for MEDP stock is "Strong Buy." The 12-month stock price forecast is $447.14, which is an increase of 10.56% from the latest price.

Price Target

$447.14

(10.56% upside)

Analyst Consensus: Strong Buy